Clinical Trial Update: Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 safety study of MGCD265 in subjects with advanced malignancies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• MGCD265 (MGCD265)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Advanced Cancer | Phase 1 | Status: COMPLETED